Department of Health Policy and Management, Emory University, Atlanta, Georgia 30322, USA.
Cancer. 2010 Oct 1;116(19):4456-62. doi: 10.1002/cncr.25208.
The National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides free or low-cost breast and cervical cancer screening to low-income, uninsured or underinsured women. The authors analyzed the impact of the NBCCEDP on breast cancer mortality rates.
The data consisted of observations for each state and year for the period from 1990 through 2004. The outcome variable was the breast cancer mortality rate for women ages 40 to 64 years. Independent variables included the proportion of women ages 40 to 64 years screened under NBCCEDP. The impact of screening intensity was estimated using least-squares regression with state and year fixed effects.
In 2004, 1.2% of women ages 40 to 64 years were screened under NBCCEDP. The NBCCEDP screening rate was related significantly and negatively to breast cancer mortality in the same year. Results indicate that, for every 1000 women screened, there were 0.6 fewer deaths because of breast cancer among women ages 40 to 64 years. Changes in screening rates were unrelated to breast cancer mortality≥2 years in the future.
In the current study, there was some evidence suggesting that the NBCCEDP led to a reduction in breast cancer mortality rates. However, the failure to detect an impact of screening on mortality rates in subsequent years suggests that caution is needed in interpreting these results as strong evidence in favor of the effectiveness of the NBCCEDP in reducing breast cancer mortality.
国家乳腺癌和宫颈癌早期检测计划(NBCCEDP)为低收入、没有保险或保险不足的妇女提供免费或低成本的乳腺癌和宫颈癌筛查。作者分析了 NBCCEDP 对乳腺癌死亡率的影响。
数据包括 1990 年至 2004 年期间每个州和年份的观察结果。因变量是 40 至 64 岁妇女的乳腺癌死亡率。自变量包括在 NBCCEDP 下接受筛查的 40 至 64 岁妇女的比例。使用具有州和年份固定效应的最小二乘法回归来估计筛查强度的影响。
2004 年,40 至 64 岁的妇女中有 1.2%在 NBCCEDP 下接受了筛查。NBCCEDP 筛查率与同年的乳腺癌死亡率呈显著负相关。结果表明,每筛查 1000 名妇女,40 至 64 岁妇女中就有 0.6 人因乳腺癌死亡。筛查率的变化与未来 2 年以上的乳腺癌死亡率无关。
在本研究中,有一些证据表明 NBCCEDP 导致了乳腺癌死亡率的降低。然而,未能检测到筛查对随后几年死亡率的影响表明,在将这些结果解释为支持 NBCCEDP 在降低乳腺癌死亡率方面有效性的有力证据时需要谨慎。